adenine has been researched along with Hematologic Diseases in 19 studies
Hematologic Diseases: Disorders of the blood and blood forming tissues.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Twelve patients with recurrent, metastatic, or inoperable gastric adenocarcinoma were enrolled in an Illinois Cancer Center phase II trial of amonafide (nafidimide), a novel compound that acts as a DNA intercalator." | 9.07 | Phase II study of amonafide in gastric adenocarcinoma. An Illinois Cancer Center trial. ( Bauman, A; Benson, AB; Blough, RR; Carroll, RB; French, SL; Kilton, LJ; Mullane, MR; Schilsky, RL; Wade, JL, 1994) |
| "Twelve patients with recurrent, metastatic, or inoperable gastric adenocarcinoma were enrolled in an Illinois Cancer Center phase II trial of amonafide (nafidimide), a novel compound that acts as a DNA intercalator." | 5.07 | Phase II study of amonafide in gastric adenocarcinoma. An Illinois Cancer Center trial. ( Bauman, A; Benson, AB; Blough, RR; Carroll, RB; French, SL; Kilton, LJ; Mullane, MR; Schilsky, RL; Wade, JL, 1994) |
| "Twenty evaluable patients with squamous cell carcinoma of the cervix, who had previously received a cisplatin-containing regimen, were treated with amonafide 300 mg/m2 over 1 hour for 5 consecutive days every 3 weeks." | 2.67 | A Gynecologic Oncology Group phase II study of amonafide (NSC #308847) in squamous cell carcinoma of the cervix. ( Asbury, RF; Blessing, JA; Soper, JT, 1994) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 5 (26.32) | 18.7374 |
| 1990's | 3 (15.79) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 8 (42.11) | 24.3611 |
| 2020's | 3 (15.79) | 2.80 |
| Authors | Studies |
|---|---|
| Abeykoon, JP | 1 |
| Zanwar, S | 1 |
| Ansell, SM | 1 |
| Gertz, MA | 1 |
| Kumar, S | 1 |
| Manske, M | 1 |
| Novak, AJ | 1 |
| King, R | 1 |
| Greipp, P | 1 |
| Go, R | 1 |
| Inwards, D | 1 |
| Muchtar, E | 1 |
| Habermann, T | 1 |
| Witzig, TE | 1 |
| Thompson, CA | 1 |
| Dingli, D | 1 |
| Lacy, MQ | 1 |
| Leung, N | 1 |
| Dispenzieri, A | 1 |
| Gonsalves, W | 1 |
| Warsame, R | 1 |
| Kyle, RA | 1 |
| Rajkumar, V | 1 |
| Parikh, SA | 2 |
| Kapoor, P | 1 |
| Munir, T | 1 |
| Brown, JR | 2 |
| O'Brien, S | 1 |
| Barrientos, JC | 1 |
| Barr, PM | 2 |
| Reddy, NM | 1 |
| Coutre, S | 2 |
| Tam, CS | 1 |
| Mulligan, SP | 1 |
| Jaeger, U | 1 |
| Kipps, TJ | 1 |
| Moreno, C | 1 |
| Montillo, M | 1 |
| Burger, JA | 1 |
| Byrd, JC | 2 |
| Hillmen, P | 1 |
| Dai, S | 1 |
| Szoke, A | 1 |
| Dean, JP | 1 |
| Woyach, JA | 2 |
| Hardy-Abeloos, C | 1 |
| Pinotti, R | 1 |
| Gabrilove, J | 1 |
| Le Gouill, S | 1 |
| Morschhauser, F | 1 |
| Chiron, D | 1 |
| Bouabdallah, K | 1 |
| Cartron, G | 1 |
| Casasnovas, O | 1 |
| Bodet-Milin, C | 1 |
| Ragot, S | 1 |
| Bossard, C | 1 |
| Nadal, N | 1 |
| Herbaux, C | 1 |
| Tessoulin, B | 1 |
| Tchernonog, E | 1 |
| Rossi, C | 1 |
| McCulloch, R | 1 |
| Gastinne, T | 1 |
| Callanan, MB | 1 |
| Rule, S | 2 |
| Robier, C | 1 |
| Beham-Schmid, C | 1 |
| Neubauer, M | 1 |
| Ruppert, AS | 1 |
| Heerema, NA | 1 |
| Zhao, W | 1 |
| Booth, AM | 1 |
| Ding, W | 1 |
| Bartlett, NL | 1 |
| Brander, DM | 1 |
| Rogers, KA | 1 |
| Hurria, A | 1 |
| Lozanski, G | 1 |
| Blachly, JS | 1 |
| Ozer, HG | 1 |
| Major-Elechi, B | 1 |
| Fruth, B | 1 |
| Nattam, S | 1 |
| Larson, RA | 1 |
| Erba, H | 1 |
| Litzow, M | 1 |
| Owen, C | 1 |
| Kuzma, C | 1 |
| Abramson, JS | 1 |
| Little, RF | 1 |
| Smith, SE | 1 |
| Stone, RM | 1 |
| Mandrekar, SJ | 1 |
| Quinquenel, A | 1 |
| Godet, S | 1 |
| Dartigeas, C | 1 |
| Ysebaert, L | 2 |
| Dupuis, J | 2 |
| Ohanyan, H | 1 |
| Collignon, A | 1 |
| Gilardin, L | 1 |
| Lepretre, S | 1 |
| Dilhuydy, MS | 2 |
| Vignon, M | 1 |
| de Guibert, S | 2 |
| Dmytruk, N | 1 |
| Durot, E | 1 |
| Ghez, D | 2 |
| Roos Weil, D | 1 |
| Béné, MC | 1 |
| Toussaint, E | 1 |
| Merabet, F | 1 |
| Lévy, V | 1 |
| Delmer, A | 2 |
| Aurran, T | 1 |
| Shah, N | 1 |
| Hutchinson, C | 1 |
| Smith, LL | 1 |
| Iskierka-Jażdżewska, E | 1 |
| Hus, M | 1 |
| Giannopoulos, K | 1 |
| Mądro, E | 1 |
| Hołojda, J | 1 |
| Piotrowska, M | 1 |
| Zaucha, JM | 1 |
| Piszczek, W | 1 |
| Szeremet, A | 1 |
| Wojciechowska, M | 1 |
| Steckiewicz, P | 1 |
| Knopińska-Posłuszny, W | 1 |
| Osowiecki, M | 1 |
| Drozd-Sokołowska, J | 1 |
| Kumiega, B | 1 |
| Kyrcz-Krzemień, S | 1 |
| Hałka, J | 1 |
| Dudziński, M | 1 |
| Wieszczy, P | 1 |
| Robak, T | 1 |
| Warzocha, K | 1 |
| Jamroziak, K | 1 |
| Michallet, AS | 1 |
| Campidelli, A | 1 |
| Lequeu, H | 1 |
| Tournilhac, O | 1 |
| Fornecker, LM | 1 |
| Cymbalista, F | 1 |
| Vilque, JP | 1 |
| Leblond, V | 1 |
| Subtil, F | 1 |
| Feugier, P | 1 |
| PAOLINO, W | 2 |
| VERCELLINO, E | 2 |
| Mullane, MR | 1 |
| Schilsky, RL | 1 |
| Carroll, RB | 1 |
| Wade, JL | 1 |
| Kilton, LJ | 1 |
| Blough, RR | 1 |
| Bauman, A | 1 |
| French, SL | 1 |
| Benson, AB | 1 |
| Asbury, RF | 1 |
| Blessing, JA | 1 |
| Soper, JT | 1 |
| Valentine, WN | 1 |
| Paglia, DE | 1 |
| Syllm-Rapoport, I | 2 |
| Jacobasch, G | 2 |
| Prehn, S | 2 |
| Rapoport, S | 2 |
| Waller, HD | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Implanted Loop Recorders (ILR) for the Detection and Management of Arrhythmia in Patients Treated With Bruton Tyrosine Kinase (BTK) Inhibitors[NCT05643235] | 50 participants (Anticipated) | Interventional | 2022-11-01 | Recruiting | |||
| A Randomized, Multicenter, Open-label, Phase 3 Study of the Bruton's Tyrosine Kinase (BTK) Inhibitor Ibrutinib (PCI-32765) Versus Ofatumumab in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma[NCT01578707] | Phase 3 | 391 participants (Actual) | Interventional | 2012-06-30 | Completed | ||
| A Phase I/II Trial of Obinutuzumab, ABT-199 (GDC-0199) Plus Ibrutinib in Relapsed / Refractory Mantle Cell Lymphoma Patients[NCT02558816] | Phase 1/Phase 2 | 48 participants (Actual) | Interventional | 2015-10-14 | Active, not recruiting | ||
| A Prospective Cohort of Obinutuzumab and Chlorambucil (GC) Chemotherapy for the Treatment of Elderly Patients With Chronic Lymphocytic Leukemia Including Next- Generation Sequencing (NGS)-Based Assessment[NCT04059081] | Phase 2 | 31 participants (Anticipated) | Interventional | 2019-07-09 | Recruiting | ||
| A Randomized Phase III Study of Bendamustine Plus Rituximab Versus Ibrutinib Plus Rituximab Versus Ibrutinib Alone in Untreated Older Patients (>/= 65 Years of Age) With Chronic Lymphocytic Leukemia (CLL)[NCT01886872] | Phase 3 | 547 participants (Actual) | Interventional | 2013-12-09 | Active, not recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
OS analysis was conducted at the time of study closure, with no adjustment for crossover from the ofatumumab arm to the ibrutinib arm (NCT01578707)
Timeframe: OS analysis was conducted at the time of study closure, including up to 6 years of study follow-up
| Intervention | months (Median) |
|---|---|
| Ofatumumab (Arm A) | 65.1 |
| Ibrutinib (Arm B) | 67.7 |
Overall Response Rate per the IWCLL 2008 criteria as assessed by IRC, limited to the time of primary analysis 06 November 2013 (NCT01578707)
Timeframe: About 18 months after the first subject was enrolled
| Intervention | percentage of participants (Number) |
|---|---|
| Ofatumumab (Arm A) | 4.1 |
| Ibrutinib (Arm B) | 42.6 |
Overall response per the IWCLL 2008 criteria as assessed by Investigator with up to 6 years of study follow-up (NCT01578707)
Timeframe: From study initiation to study closure, including up to 6 years of study follow-up
| Intervention | percentage of participants (Number) |
|---|---|
| Ofatumumab (Arm A) | 22.4 |
| Ibrutinib (Arm B) | 87.7 |
The primary objective of this study was to evaluate the efficacy of ibrutinib compared to ofatumumab based on independent review committee (IRC) assessment of progression-free survival (PFS) according to 2008 IWCLL guidelines. (NCT01578707)
Timeframe: Analysis was conducted after observing approximately 117 PFS events, which occurred about 18 months after the first subject was enrolled.
| Intervention | months (Median) |
|---|---|
| Ofatumumab (Arm A) | 8.1 |
| Ibrutinib (Arm B) | NA |
Long-Term Progression Free Survival as assessed by the investigator with up to 6 years of study follow-up (NCT01578707)
Timeframe: From study initiation to study closure, including up to 6 years of study follow-up
| Intervention | months (Median) |
|---|---|
| Ofatumumab (Arm A) | 8.1 |
| Ibrutinib (Arm B) | 44.1 |
Proportion of subjects with hemoglobin (HgB) increase >=20 g/L and platelet (PLT) increase >=50% over baseline continuously for >=56 days without blood transfusions or growth factors. (NCT01578707)
Timeframe: From study initiation to study closure, including up to 6 years of study follow-up
| Intervention | percentage of participants (Number) | |
|---|---|---|
| Hgb Improvement in patient with baseline anemia | Platelet improvement in baseline thrombocytopenia | |
| Ibrutinib (Arm B) | 69.7 | 78.4 |
| Ofatumumab (Arm A) | 32.6 | 9.4 |
The Kaplan-Meier method will be used to estimate median DOR. DOR is the time from first objective status to progression or death. CR requires all of the following: absence of lymphadenopathy > 1.5 cm on physical exam/CT scan, no hepatomegaly/splenomegaly on physical exam, no clonal B-cells in the blood, Normal CBC, bone marrow aspirate & biopsy must be normocellular for age. PR requires >= 50% decrease in peripheral lymphocyte count from pre-treatment value, >= 50% reduction in lymphadenopathy, and/or ≥ 50% reduction in splenomegaly/hepatomegaly. CR with exception of having bone marrow lymphoid CLL nodules will be considered a nodular PR (nPR). CR with exception of not having a bone marrow biopsy performed will be considered a clinical CR (CCR). PR with the exception of having less than a 50% reduction in peripheral lymphocyte count will be considered a PR except persistent lymphocytosis (PRL). (NCT01886872)
Timeframe: From the date of first response until progression or death, performed at 2.5 years after the last patient enrolled; up to 4 years.
| Intervention | months (Median) |
|---|---|
| Arm A (Rituximab, Bendamustine Hydrochloride) | 50 |
| Arm B (Ibrutinib) | NA |
| Arm C (Ibrutinib, Rituximab) | NA |
The Kaplan-Meier method will be used to estimate the rate of overall survival at 2 years in each treatment arm. OS will be measured from the date of registration to the date of the event (i.e., death) or the date of last follow-up to evaluate that event. Patients who are event-free at their last follow-up evaluation will be censored at that time point. (NCT01886872)
Timeframe: From the date of registration to the date of death, assessed up to 2 years
| Intervention | percentage of patients (Number) |
|---|---|
| Arm A (Rituximab, Bendamustine Hydrochloride) | 95 |
| Arm B (Ibrutinib) | 90 |
| Arm C (Ibrutinib, Rituximab) | 94 |
Complete response (CR) requires all of the following: absence of lymphadenopathy > 1.5 cm on physical exam/CT scan, no hepatomegaly or splenomegaly on physical exam, no clonal B-cells in the blood, Normal CBC, bone marrow aspirate and biopsy must be normocellular for age. Complete response rate and corresponding exact binomial 95% confidence intervals provided. (NCT01886872)
Timeframe: Performed at 2.5 years after the last patient enrolled; up to 4 years.
| Intervention | percentage of patients (Number) |
|---|---|
| Arm A (Rituximab, Bendamustine Hydrochloride) | 26 |
| Arm B (Ibrutinib) | 7 |
| Arm C (Ibrutinib, Rituximab) | 12 |
Complete response (CR) requires all of the following: absence of lymphadenopathy >1.5 cm on physical exam/CT scan, no hepatomegaly/splenomegaly on physical exam, no clonal B-cells in the blood, Normal CBC, bone marrow aspirate & biopsy must be normocellular for age. Partial response (PR) requires >= 50% decrease in peripheral lymphocyte count from pre-treatment value, >= 50% reduction in lymphadenopathy, and/or ≥ 50% reduction in splenomegaly/hepatomegaly. CR with exception of having bone marrow lymphoid CLL nodules will be considered a nodular PR (nPR). CR with exception of not having a bone marrow biopsy performed will be considered a clinical CR (CCR). PR with the exception of having less than a 50% reduction in peripheral lymphocyte count will be considered a PR except persistent lymphocytosis (PRL).Overall response rate and corresponding exact binomial 95% CI provided. (NCT01886872)
Timeframe: Performed at 2.5 years after the last patient enrolled;up to 4 years.
| Intervention | percentage of patients (Number) |
|---|---|
| Arm A (Rituximab, Bendamustine Hydrochloride) | 75 |
| Arm B (Ibrutinib) | 93 |
| Arm C (Ibrutinib, Rituximab) | 94 |
Complete response (CR) requires all of the following: absence of lymphadenopathy > 1.5 cm on physical exam/CT scan, no hepatomegaly or splenomegaly on physical exam, no clonal B-cells in the blood, Normal CBC, bone marrow aspirate and biopsy must be normocellular for age. CR with exception of having bone marrow lymphoid CLL nodules will be considered a nodular PR (nPR). CR with exception of not having a bone marrow biopsy performed will be considered a clinical CR (CCR). Response rate and corresponding exact binomial 95% confidence intervals provided. (NCT01886872)
Timeframe: Performed at 2.5 years after the last patient enrolled; up to 4 years.
| Intervention | percentage of patients (Number) |
|---|---|
| Arm A (Rituximab, Bendamustine Hydrochloride) | 33 |
| Arm B (Ibrutinib) | 10 |
| Arm C (Ibrutinib, Rituximab) | 23 |
Estimated using the number of patients who achieve minimal residual disease divided by the total number randomized to that treatment arm. Corresponding exact binomial 95% confidence intervals for MRD rates will be calculated. (NCT01886872)
Timeframe: Cycle 9 Day 1 Evaluation
| Intervention | percentage of patients (Number) |
|---|---|
| Arm A (Rituximab, Bendamustine Hydrochloride) | 8 |
| Arm B (Ibrutinib) | 1 |
| Arm C (Ibrutinib, Rituximab) | 4 |
The Kaplan-Meier method will be used to estimate the progression free survival distributions for each arm, with median estimates provided. Progression is defined as any one of the following: an increase in number of blood lymphocytes by >= 50% with >= 5000 B lymphocytes/mL in patients on Arm A or those on Arms 2 or 3 no longer receiving ibrutinib, >= 50% increase in the products of at least 2 lymph nodes on 2 consecutive determination 2 weeks apart, >= 50% increase in the size of the liver/spleen, transformation to a more aggressive histology, progression of any cytopenia (i.e. decrease of Hb levels > 2g/dL). Progression free survival time will be the time to either progression or death whichever occurs first. (NCT01886872)
Timeframe: Time from study entry to the time of documented disease progression or death. The analysis was event driven, performed at 2.5 years after the last patient enrolled;up to 4 years.
| Intervention | months (Median) |
|---|---|
| Arm A (Rituximab, Bendamustine Hydrochloride) | 43 |
| Arm B (Ibrutinib) | NA |
| Arm C (Ibrutinib, Rituximab) | NA |
The Kaplan-Meier method will be used to estimate the rate of progression free survival at 2 years in each treatment arm. Progression is defined as any one of the following: an increase in number of blood lymphocytes by >= 50%, >= 50% increase in the products of at least 2 lymph nodes on 2 consecutive determination 2 weeks apart, >= 50% increase in the size of the liver/spleen, transformation to a more aggressive histology, progression of any cytopenia (i.e. decrease of Hb levels > 2g/dL). Progression free survival time will be the time to either progression or death whichever occurs first. (NCT01886872)
Timeframe: Time from study entry to the time of documented disease progression or death, assessed up to 2 years
| Intervention | percentage of patients (Number) |
|---|---|
| Arm A (Rituximab, Bendamustine Hydrochloride) | 74 |
| Arm B (Ibrutinib) | 87 |
| Arm C (Ibrutinib, Rituximab) | 88 |
The rate of grade 3, 4, or 5 treatment-related non-hematologic adverse events (toxicities) by arm; excludes adverse events occurring post-crossover for patients in Arm A (NCT01886872)
Timeframe: Performed at 2.5 years after the last patient enrolled; up to 4 years.
| Intervention | percentage of patients (Number) |
|---|---|
| Arm A (Rituximab, Bendamustine Hydrochloride) | 41 |
| Arm B (Ibrutinib) | 48 |
| Arm C (Ibrutinib, Rituximab) | 39 |
2 reviews available for adenine and Hematologic Diseases
| Article | Year |
|---|---|
Ibrutinib dose modifications in the management of CLL.
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Antineoplastic Agents; Biotransformation; Clinical Stu | 2020 |
Red cell metabolism, normal and abnormal implications for red cell aging.
Topics: Adenine; Adenine Nucleotides; Adenosine; Adenosine Deaminase; Adenosine Kinase; Adenosine Monophosph | 1991 |
6 trials available for adenine and Hematologic Diseases
| Article | Year |
|---|---|
Final analysis from RESONATE: Up to six years of follow-up on ibrutinib in patients with previously treated chronic lymphocytic leukemia or small lymphocytic lymphoma.
Topics: Adenine; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, I | 2019 |
Final analysis from RESONATE: Up to six years of follow-up on ibrutinib in patients with previously treated chronic lymphocytic leukemia or small lymphocytic lymphoma.
Topics: Adenine; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, I | 2019 |
Final analysis from RESONATE: Up to six years of follow-up on ibrutinib in patients with previously treated chronic lymphocytic leukemia or small lymphocytic lymphoma.
Topics: Adenine; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, I | 2019 |
Final analysis from RESONATE: Up to six years of follow-up on ibrutinib in patients with previously treated chronic lymphocytic leukemia or small lymphocytic lymphoma.
Topics: Adenine; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, I | 2019 |
Ibrutinib, obinutuzumab, and venetoclax in relapsed and untreated patients with mantle cell lymphoma: a phase 1/2 trial.
Topics: Adenine; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemoth | 2021 |
Ibrutinib Regimens versus Chemoimmunotherapy in Older Patients with Untreated CLL.
Topics: Adenine; Aged; Aged, 80 and over; Bendamustine Hydrochloride; Drug Therapy, Combination; Female; Fol | 2018 |
Ibrutinib Regimens versus Chemoimmunotherapy in Older Patients with Untreated CLL.
Topics: Adenine; Aged; Aged, 80 and over; Bendamustine Hydrochloride; Drug Therapy, Combination; Female; Fol | 2018 |
Ibrutinib Regimens versus Chemoimmunotherapy in Older Patients with Untreated CLL.
Topics: Adenine; Aged; Aged, 80 and over; Bendamustine Hydrochloride; Drug Therapy, Combination; Female; Fol | 2018 |
Ibrutinib Regimens versus Chemoimmunotherapy in Older Patients with Untreated CLL.
Topics: Adenine; Aged; Aged, 80 and over; Bendamustine Hydrochloride; Drug Therapy, Combination; Female; Fol | 2018 |
Ibrutinib and idelalisib in the management of CLL-associated autoimmune cytopenias: a study from the FILO group.
Topics: Adenine; Autoimmune Diseases; Disease-Free Survival; Female; Hematologic Diseases; Humans; Leukemia, | 2019 |
Phase II study of amonafide in gastric adenocarcinoma. An Illinois Cancer Center trial.
Topics: Adenine; Adenocarcinoma; Antineoplastic Agents; Female; Hematologic Diseases; Humans; Imides; Isoqui | 1994 |
A Gynecologic Oncology Group phase II study of amonafide (NSC #308847) in squamous cell carcinoma of the cervix.
Topics: Adenine; Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcino | 1994 |
11 other studies available for adenine and Hematologic Diseases
| Article | Year |
|---|---|
Ibrutinib monotherapy outside of clinical trial setting in Waldenström macroglobulinaemia: practice patterns, toxicities and outcomes.
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Aged; Aged, 80 and over; Antineoplastic Agents; Diseas | 2020 |
Spuriously low lymphocyte count associated with pseudoerythroblastemia in a patient with chronic lymphocytic leukemia treated with ibrutinib.
Topics: Adenine; Female; Hematologic Diseases; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphocyte Co | 2018 |
Ibrutinib for the treatment of mantle cell lymphoma.
Topics: Adenine; Adult; Agammaglobulinaemia Tyrosine Kinase; Aged; Aged, 80 and over; Antibodies, Monoclonal | 2014 |
58th American Society of Hematology Annual Meeting.
Topics: ADAMTS13 Protein; Adenine; Antibodies, Monoclonal; Antineoplastic Agents; Central Venous Catheters; | 2017 |
Efficacy and toxicity of compassionate ibrutinib use in relapsed/refractory chronic lymphocytic leukemia in Poland: analysis of the Polish Adult Leukemia Group (PALG).
Topics: Adenine; Adult; Aged; Aged, 80 and over; Drug Resistance, Neoplasm; Female; Follow-Up Studies; Hemat | 2017 |
Ibrutinib in very elderly patients with relapsed/refractory chronic lymphocytic leukemia: A real-world experience of 71 patients treated in France: A study from the French Innovative Leukemia Organization (FILO) group.
Topics: Adenine; Aged; Aged, 80 and over; Antineoplastic Agents; Cardiovascular Diseases; Dose-Response Rela | 2017 |
[Experimental studies of the preventive and curative effectiveness of adenine in hematological damage caused by acute benzol intoxication].
Topics: Adenine; Benzene; Drug-Related Side Effects and Adverse Reactions; Hematologic Diseases; Humans; Psy | 1959 |
Effects of adenine on blood disease due to benzene poisoning.
Topics: Adenine; Benzene; Hematologic Diseases; Humans | 1960 |
[On the increase in adenine nucleotides in transfused erythrocytes in congenital erythroblastopenia].
Topics: Adenine; Adenine Nucleotides; Adenosine Triphosphate; Blood Transfusion; Bone Marrow; Child, Prescho | 1968 |
[Congenital enzyme defects as a cause of blood disorders].
Topics: Adenine; Anemia, Hemolytic; Anemia, Hemolytic, Congenital; Anemia, Hypochromic; Anemia, Macrocytic; | 1971 |
On a regulatory system of the adenine level in the plasma connected with red cell maturation and its effect on the adenine nucleotides of the circulating erythrocyte. Lack of relation between ATP-level and life span of the erythrocyte.
Topics: Adenine; Adenine Nucleotides; Adenosine Triphosphate; Blood Transfusion; Bone Marrow Cells; Child; E | 1969 |